Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) (the “Company”) has announced that Ms. Chan Hiu Lam has resigned from her roles as a Joint Company Secretary, Authorized Representative under the Listing Rules and Companies Ordinance, as well as Process Agent, effective 21 November 2025. According to the announcement, Ms. Chan confirmed there is no disagreement with the board of directors, and no matter relating to her resignation requires the attention of the Stock Exchange or the shareholders.

Effective the same date, Ms. Lam Wai Yee Sophie will be appointed as Joint Company Secretary, Authorized Representative, and Process Agent. Ms. Lam brings more than 20 years of company secretarial and compliance experience, having provided services in similar capacities to various companies listed on the Main Board of the Stock Exchange. She will work alongside the current Joint Company Secretary, Ms. Zhang Junhuan.

Furthermore, the announcement notes that the Stock Exchange has granted a revised waiver regarding the qualification of Ms. Zhang to act as a Joint Company Secretary. The revised waiver is valid from 21 November 2025 to 19 October 2028, subject to the condition that Ms. Zhang be assisted by Ms. Lam during this period and that there be no material breach of the Listing Rules by the Company. Before the waiver expires, the Company must demonstrate that Ms. Zhang has attained the requisite experience to discharge the duties of a company secretary without further waiver.

The board expressed gratitude for Ms. Chan’s contributions and extended a welcome to Ms. Lam on her new appointments.